Latest Biotech News

Solstice Oncology emerged from stealth with a $225 million Series A designed to advance porustobart, its next-generation CTLA-4 antibody built for microsatellite-stable (MSS) colon cancer. The...

Two developments sharpen the evidence base around cryoablation for cancer. One new AI model aims to predict cryoablation failure by measuring tumor contact with the renal sinus, using imaging to...

Researchers reported in Science Translational Medicine that highly specific monoclonal antibodies targeting MMP-9 can slow and even reverse diabetic nerve pain in mouse models. The work focuses on...

Axogen agreed to acquire Biocircuit Technologies in a $200 million cash transaction, extending the company’s footprint in peripheral nerve repair. The deal brings Nerve Tape, described as the...

Teijin, Teijin Regenet, and Shinshu University Hospital launched a joint research agreement focused on manufacturing technologies for cell and gene therapy products, with an emphasis on...

Cedars-Sinai researchers reported in Cell Metabolism that PD-L2 can function as an immune checkpoint on senescent cells, enabling them to evade clearance and accumulate during aging. The team...

ARPA-H launched ADVOCATE, a program meant to build FDA-authorized agentic AI tools, and named UpDoc, Tempus AI, and Atman Health as participants for heart disease use cases. The effort builds on...

Researchers used AI to map collagen “highways” and myeloid roadblocks that trap T cells in pancreatic ductal adenocarcinoma, targeting a key mechanistic barrier to immunotherapy. The work,...

A report highlighted how Wall Street’s “shell” vehicle market has revived in biotech, with reverse mergers more than doubling year-over-year amid investor demand for public listings. Dealmakers...

The FDA moved to expand access for Bayer’s Hyrnuo (sevabertinib) in HER2-mutated lung cancer, granting an accelerated approval expansion to first-line patients with locally advanced or metastatic...

Solstice Oncology emerged from stealth and anchored its next step in CTLA-4 immunotherapy with a new $225 million Series A, led by RA Capital Management and joined by other investors including...

Biohaven’s epilepsy program ran into a regulatory speed bump as the FDA issued a partial clinical hold on its ion-channel drug, BHV-7000, requesting additional preclinical safety information that...

The sector’s funding engine kept running, with multiple large checks signaling investors’ continued appetite for both early clinical and enabling platforms. Archimed closed its MED IV fund at €1.5...

Echo IQ Ltd. disclosed a regulatory detour for its AI heart failure diagnostic ambitions after the FDA issued a not substantially equivalent determination for the company’s initial 510(k)...

Salk Institute researchers tied a key immune paradox to mitochondria and interferon signaling, reporting that chronic type II interferon exposure promotes tumor growth via mitochondrial...

BMS delivered a targeted performance boost in multiple myeloma cell therapy with new data for its BCMA CAR T, arlocabtagene autoleucel, in the QUINTESSENTIAL study. The trial met its overall...

New AI frameworks aimed at decoding complex biology and clinical workflows pushed into the spotlight, including a method to better predict hippocampal cognitive decline by layering polygenic risk...

A series of preclinical and early research updates pointed to mechanism-driven oncology hypotheses. Researchers described how colorectal cancer cells can hijack interferon beta signaling through...

A targeted NIH award backed new leukemia immunotherapy research at SUNY Upstate Medical University, with $3.3 million funding aimed at strategies to counter leukemia’s immune evasion in acute...

The FDA moved to stabilize leadership across its drug and biologics review centers, with Michael Davis and Karim Mikhail promoted from acting to permanent directors. The shift comes as the agency...